Clinical trials
Atopic Dermatitis clinical trials
Below are recruiting atopic dermatitis clinical trials, each written for real people, not researchers. We’re tracking 177 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07754786RecruitingPhase 3
Comparing a new eczema medicine with dupilumab
This study tests whether a new biologic medicine (IBI3027) works as well as an approved medicine (dupilumab) for treating moderate-to-severe eczema. If you join, you may receive one of the two treatments, and researchers will compare their effects on your skin and itching.
Guangzhou, GuangdongAges 18–75 - NCT05285839RecruitingPhase 4
Dupixent plus UVB light for moderate to severe eczema
This study tests whether taking Dupixent and receiving narrowband UVB light can improve moderate to severe atopic dermatitis (eczema). It may help people whose symptoms are significant despite usual care.
East Windsor, New JerseyAges 18 years+ - NCT06390696Recruiting
Sand play for eczema: a biodiversity study
This study looks at whether playing in sand with different types of natural materials (to increase your contact with harmless microbes) can improve eczema symptoms. You would stop using your usual eczema creams during the trial to see if the sand play alone helps.
Helsinki, UusimaaAges 2–5 - NCT07800104RecruitingPhase 1
Study of a new pill for moderate-to-severe eczema
This trial tests an experimental medicine called QX-4533. The study has two parts: one tests the drug in healthy volunteers, and the other tests it in people with moderate-to-severe atopic dermatitis (a type of eczema) that hasn't responded well to standard creams. The goal is to see if the drug is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 1.5 years–65 years - NCT07746817RecruitingPhase 1
Study of a new drug for eczema
This study tests a new drug called BYN-001 in two groups: healthy people and people with moderate to severe eczema (atopic dermatitis). The goal is to see if the drug is safe and how well it works.
Melbourne, VictoriaAges 18–55 - NCT07746427Recruiting
Mindfulness program on a phone or tablet for teens with eczema
This study tests a digital mindfulness program to help teens manage their eczema. It looks at whether this approach can reduce symptoms and improve quality of life.
New York, New YorkAges 13–17 - NCT07734415Enrolling by invitationPhase 2
Long-term safety of IMG-007 for moderate-to-severe eczema
This study checks the long-term safety and effectiveness of IMG-007 in people with moderate-to-severe atopic dermatitis (eczema) who have already finished a previous IMG-007 trial.
Lancaster, CaliforniaAges 18–75 - NCT07730788Recruiting
Skin imaging study in eczema patients receiving nemolizumab
This trial tests whether a special skin imaging technique (reflectance confocal microscopy) can see how nemolizumab changes the skin structure in people with moderate-to-severe eczema. It may help researchers understand how this treatment works.
Romans-sur-Isère, DrômeAges 18 years+ - NCT06362629Recruiting
Smartphone App for Managing Eczema
This trial tests a smartphone app designed to help people manage their atopic dermatitis (eczema). If you or your child has eczema and can use a smartphone, this app may help track symptoms and provide advice.
Chengdu, SichuanAges 1–75 - NCT07659756Recruiting
Global study on atopic dermatitis (eczema)
This study gathers information from people around the world who have atopic dermatitis (eczema). It aims to better understand the condition and how it affects people's lives.
ZurichAges 14 years+ - NCT07643766RecruitingPhase 2
Testing ENV-294 for moderate-to-severe atopic dermatitis
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
Encinitas, CaliforniaAges 18 years+ - NCT07629778RecruitingPhase 1/Phase 2
HL-300 Ointment for Mild-to-Moderate Atopic Dermatitis
This study tests a new ointment (HL-300) designed to treat mild-to-moderate atopic dermatitis (a chronic skin condition causing itching and inflammation). You would apply it to affected skin areas to see if it safely reduces symptoms.
Hangzhou, ZhejiangAges 18–75 - NCT07604324RecruitingPhase 1
New Drug for Moderate to Severe Eczema Treatment
This study tests a new investigational drug called DCY636 to see if it can help people with moderate to severe atopic dermatitis (eczema) that hasn't improved with topical creams. The trial starts with safety testing in healthy volunteers, then moves to people with active eczema.
FukuokaAges 18–55 - NCT07598383RecruitingPhase 2
Gel treatment for mild-to-moderate atopic dermatitis
This study tests a new gel called VC005 to see if it safely reduces itching, redness, and irritation in people with atopic dermatitis (a chronic skin condition). You'll be randomly assigned to either the new gel or a placebo (inactive gel) and apply it to affected areas over several weeks.
Hangzhou, ZhejiangAges 18 years+ - NCT07599813RecruitingPhase 2
Testing camoteskimab for moderate-to-severe eczema
This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to creams alone. The drug works by targeting a protein in the body that causes eczema symptoms like itching and inflammation.
Birmingham, AlabamaAges 18–65 - NCT07592585RecruitingPhase 3
Testing VC005 cream for mild-to-moderate eczema in teens and adults
This study tests a new medication called VC005 to treat atopic dermatitis (eczema)—a skin condition causing itching, redness, and inflammation. Researchers want to see if VC005 can safely reduce symptoms in people aged 12 and older with mild-to-moderate cases.
Nanjing, JiangsuAges 12 years+ - NCT07573735Recruiting
Blood markers and skin inflammation in atopic dermatitis
This study examines a specific blood marker (cfDNA-STING) that may help explain why atopic dermatitis develops. Researchers will compare this marker in people with and without atopic dermatitis to understand the condition better.
Nanjing, JiangsuAges 18 years+ - NCT07503197Enrolling by invitation
Cholesterol cream for child eczema
This trial tests a 2% cholesterol cream to see if it helps children with mild to moderate eczema on their inner elbows. It's designed for Thai children aged 7 to 17 who are not using strong immune-suppressing drugs.
BangkokAges 7–17 - NCT07467564Recruiting
Does Dupilumab help anxiety and depression in eczema?
This study looks at whether Dupilumab (a treatment for moderate-to-severe eczema) can also help improve symptoms of anxiety and depression. It is for people with eczema who also have these mood symptoms and are about to start Dupilumab.
DohaAges 12 years+ - NCT07445919RecruitingPhase 2
Testing SM17 for moderate-to-severe eczema
This trial tests an investigational drug called SM17 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if SM17 can reduce itching and skin symptoms when topical treatments haven't worked well enough.
BeijingAges 18–70 - NCT07441395RecruitingPhase 2
Study of soquelitinib for moderate to severe eczema
This trial tests an experimental pill called soquelitinib for people with moderate to severe eczema (atopic dermatitis). It aims to see if the drug can reduce symptoms like itching and skin inflammation.
South San Francisco, CaliforniaAges 18 years+ - NCT06815380Recruiting
Study on lebrikizumab for people with atopic dermatitis
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
Aarhus, DenmarkAges 18 years+ - NCT07399067RecruitingPhase 2
Testing IBI3002 for moderate to severe eczema
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
Beijing, Beijing MunicipalityAges 18–75 - NCT07355075RecruitingPhase 2/Phase 3
Study of a new cream for moderate to severe eczema
This study tests an investigational cream for moderate to severe eczema. It helps see if the cream reduces symptoms like itching and skin inflammation.
Irving, TexasAges 18–80
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Atopic Dermatitis trials by city
Studies with a site in or near these metro areas.
Atopic Dermatitis trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for atopic dermatitis?
- Yes. Clin2 currently lists 177 recruiting atopic dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a atopic dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.